pharmaceutical products - the subject of this publication is the conclusion of non-exclusive discount agreements in accordance with section 130a (8) sgb v for drugs with the active ingredient tolvaptan (official atc code: g04bx21). the contract is concluded in the context of a so-called open house model, i. h. a contract is open to all interested pharmaceutical companies during the participation period, provided that they meet and accept the participation requirements. as a result, individual contract negotiations are not conducted and there is no (delivery) exclusivity. it should be noted that the purchase quantity is unknown, as this depends on demand and the development of the number of insured persons, on the preion behavior of doctors and the dispensing and stocking behavior of public pharmacies. accordingly, minimum purchase quantities are not guaranteed. for more information, please refer to point ii.2.4) of the notice.